阿仑单抗与自体造血干细胞移植对比非诱导治疗的多发性硬化安全性
基于瑞典多发性硬化登记与全国健康注册的队列研究,纳入2008-2017年启动阿仑单抗(132例)、自体造血干细胞移植(AHSCT,139例)及匹配的非诱导治疗患者(2486例)。发现阿仑单抗组甲状腺疾病发生率最高,AHSCT组感染发生率高于阿仑单抗和非诱导治疗,非甲状腺自身免疫病发生率各组相似。
要点
- 阿仑单抗治疗者甲状腺疾病发生率显著升高(IR 109/1000人年)。
- AHSCT治疗者感染(≥6个月)发生率高于阿仑单抗和非诱导治疗。
- 两种诱导治疗的非甲状腺自身免疫病发生率均较低。
核心结论
- 阿仑单抗和AHSCT治疗者甲状腺疾病发生率增高,且AHSCT感染风险高于阿仑单抗及非诱导治疗。
研究设计与样本
- 基于瑞典多发性硬化登记与全国健康注册的 population-based 队列研究,纳入2008-2017年启动治疗的患者。
- 阿仑单抗组132例,AHSCT组139例(68%接受高剂量环磷酰胺和抗胸腺细胞球蛋白,32%接受BCNU、依托泊苷、阿糖胞苷和melphalan/ATG),非诱导治疗匹配组2486例( natalizumab、富马酸二甲酯、利妥昔单抗、芬戈莫德)。
主要发现
- 阿仑单抗组死亡4例(IR 8.6/1000人年,95%CI 2.3-22.0),AHSCT组死亡1例(IR 1.7,95%CI 0.0-9.6),参考组死亡率0.7(95%CI 0.3-1.3)。
- 甲状腺疾病在阿仑单抗组最常见(IR 109,95%CI 75-154),AHSCT组亦增高(IR 34,95%CI 18-56),参考组IR 5.3(95%CI 3.9-7.1)。
- 非甲状腺自身免疫病发生率各组相似。
- 治疗开始≥6个月诊断的感染IR:阿仑单抗53(95%CI 30-87),AHSCT 108(95%CI 75-150),参考组51(95%CI 46-57)。
临床怎么用
- 阿仑单抗治疗需监测甲状腺疾病,AHSCT后需警惕感染风险。
- 非甲状腺自身免疫病风险较低,但仍需临床关注。
局限性
- 本研究为观察性队列研究,证据等级为Class III。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess safety outcomes for the induction therapies alemtuzumab and autologous hematopoietic stem cell transplantation (AHSCT) compared to noninduction disease-modifying therapies. METHODS: We performed a population-based cohort study linking the Swedish Multiple Sclerosis Register to national health care registers. Alemtuzumab, AHSCT, and a matched reference group of noninduction therapies (natalizumab, dimethyl fumarate, rituximab, fingolimod) were included if started between 2008 and 2017. Main outcomes were death, thyroid disease, nonthyroid autoimmune disease, and infection. RESULTS: We identified 132 alemtuzumab-treated and 139 AHSCT-treated (68% high-dose cyclophosphamide and anti-thymocyte globulin [ATG], 32% BCNU, etoposide, cytosine-arabinoside, and melphalan/ATG) patients, together with 2,486 matched patients treated with noninduction therapies. Four patients in the alemtuzumab group died (incidence rate [IR] per 1,000 person-years 8.6, 95% confidence interval [CI] 2.3-22.0) compared to 1 patient in the AHSCT group (IR 1.7, 95% CI 0.0-9.6), and the mortality rate in the reference group was 0.7 (95% CI 0.3-1.3). Thyroid disease was most frequent in the alemtuzumab group (IR 109, 95% CI 75-154) but also occurred more often for AHSCT (IR 34, 95% CI 18-56) compared to the reference (IR 5.3 95% CI 3.9-7.1). The incidence of nonthyroid autoimmune disease was similar in all groups. IR for infection diagnosed ≥6 months from therapy initiation was 53 (95% CI 30-87) for alemtuzumab, 108 (95% CI 75-150) for AHSCT, and 51 (95% CI 46-57) for the reference. CONCLUSION: We confirmed a high incidence of thyroid disease in alemtuzumab- and, to a smaller extent, AHSCT-treated patients and found a higher incidence of infection for AHSCT compared to both alemtuzumab and noninduction therapies. The incidence of nonthyroid autoimmune disease was low for both therapies. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence of an increased risk of thyroid disease with alemtuzumab and an increased risk of infection with AHSCT treatment.
引用
- Alping P, Burman J, Lycke J, et al. Safety of Alemtuzumab and Autologous Hematopoietic Stem Cell Transplantation Compared to Noninduction Therapies for Multiple Sclerosis. Neurology. 2021. PMID: 33514645. doi:10.1212/WNL.0000000000011545
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。